Pharmacologic profile of BN 50739, a new PAF antagonist and

Braquet, 1987, Perspective in platelet-activating factor research, Pharmacol. Rev., 39, 97 Feuerstein, 1987, Prostaglandins, leukotrienes and platelet-activating factor in shock, Ann. Rev. Pharmacol. Toxicol., 27, 301, 10.1146/annurev.pa.27.040187.001505 Cheng, 1987, Platelet-activating factor mediates hemodynamic changes and lung injury in injury in endotoxin-treated rats, J. Clin. Invest., 79, 1498, 10.1172/JCI112980 Sun, 1988, Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor, J. Clin. Invest., 81, 1328, 10.1172/JCI113459 Subissi, 1988, Effects of anti-asthma drugs on PAF-induced death in mice, Prostaglandins, 36, 797, 10.1016/0090-6980(88)90057-3 Birkle, 1988, Platelet-activating factor antagonist BN 52021 decreases accumulation of free polyunsaturated fatty acid mouse brain during ischemic and electroconvulsive shock, J. Neurochem., 51, 1900, 10.1111/j.1471-4159.1988.tb01175.x Montrucchio, 1989, Release of platelet-activating factor from ischemic-reperfused rabbit heart, Am. J. Physiol., 256, H1236 Braquet, 1989, Is there a case for PAF antagonists in the treatment of ischemic states?, TIPS, 10, 23 Handley, 1988, Development and therapeutic indications for PAF receptor antagonists, Drug of the Future, 13, 137 Godfroid, 1986, PAF-acether specific binding sites: 1. quantitative SAR study of PAF-ecether isosteres, TIPS, 7, 368 Pinckard, 1979, Physicochemical and functional identity of rabbit platelet-activating factor (PAF) released in vivo during IgE anaphylaxi with PAF release barin vitro from IgE sensitized basophils, J. Immunol., 123, 1947 Shen, 1987, The chemical and biological properties of PAF agonists, antagonists and biosynthetic inhibitors, 165 Handley, 1987, Biological properties of the antagonist SRI 63–441 in the PAF and endotoxin models of hypotension in the rat and dog, Immunopharmacol., 13, 125, 10.1016/0162-3109(87)90049-X Sanchez-Crespo, 1988, WEB 2086, Drugs of the Future, 13, 242, 10.1358/dof.1988.013.03.62409 Nunez, 1986, Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with PAF-acether inhibitors Kadsurenone and CV 3988, Eur. J. Pharmacol., 123, 197, 10.1016/0014-2999(86)90660-6 Siren, 1988, Hemodynamic neural mechanism of action of thyrotropin-releasing hormone in the rat, Cir. Res., 62, 139, 10.1161/01.RES.62.1.139 Munnucci, 1972, Methods for the preparation of washed platelet suspensions, 57, 10.1007/978-1-4684-3231-2_4 Voelkel, 1986, PAF antagonists: different effects on platelets, neutrophils, guinea pig ielum and PAF-induced vasodilation in isolated rat lung, Prostaglandins, 32, 359, 10.1016/0090-6980(86)90005-5 Namm, 1982, Specificity of the platelet responses to 1-o-alkyl-2-acetyl-sn-glycero-3-phosphocholine, Thromb. Res., 25, 341, 10.1016/0049-3848(82)90234-1 Siren, 1989, Effects of platelet-activating factor and its antagonist, BN 52021, on cardiac function and reginal blood flow in the conscious rats, Am. J. Physiol., 256, H25 Feuerstein, 1982, Cardiovascular and sympathetic effects of 1-0-hexadecyl-2-acetyl-sn-glycero-3-phosphorycholine in conscious SHR and WKY rats, Clin. Exp. Hypertens., A4, 1335, 10.3109/10641968209060793